Donald Trump promised to rein in drug prices, but his plan does little but add another battering ram to his ongoing economic war against America’s allies.
The Trump administration should veto the chemical giants' pending merger to protect not just competitors but human and environmental health.
Hospitals and pharmacies are required to discard expired drugs, no matter how costly or vital they are. Meanwhile, the FDA has long known that many remain safe and potent for years.
While in Congress, HHS Secretary Tom Price acquired up to $90,000 of pharmaceutical stock the same day he intervened on a rule that would hurt drug profits.
As it readies for battle with President Trump over drug prices, the pharmaceutical industry is deploying economists and health care experts from top universities.
Physicians whose state boards have sanctioned them for harming patients, unnecessarily prescribing addictive drugs, bilking federal insurance programs and even sexual misconduct continue to cash in for consulting, promoting products and more.
Consumers, including a ProPublica reporter, love saving money using drug copay coupons. But by upending the benefit structure of health insurers, these clever marketing tools may be increasing costs for everyone.
The Pharma-driven opioid epidemic may be as big a con as the mortgage housing bubble collapse.
Big Pharma executives are going all out to paint themselves as the good guys—just not to you.